Cargando…

Effects of Lipid-Lowering Drugs on High-Density Lipoprotein Subclasses in Healthy Men—A Randomized Trial

CONTEXT AND OBJECTIVE: Investigating the effects of lipid-lowering drugs on HDL subclasses has shown ambiguous results. This study assessed the effects of ezetimibe, simvastatin, and their combination on HDL subclass distribution. DESIGN AND PARTICIPANTS: A single-center randomized parallel 3-group...

Descripción completa

Detalles Bibliográficos
Autores principales:	Berthold, Heiner K., Rizzo, Manfredi, Spenrath, Nadine, Montalto, Giuseppe, Krone, Wilhelm, Gouni-Berthold, Ioanna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963857/ https://www.ncbi.nlm.nih.gov/pubmed/24662777 http://dx.doi.org/10.1371/journal.pone.0091565

Ejemplares similares

Effects of Lipid-Lowering Drugs on Irisin in Human Subjects In Vivo and in Human Skeletal Muscle Cells Ex Vivo
por: Gouni-Berthold, Ioanna, et al.
Publicado: (2013)

Association between the Interleukin-6 Promoter Polymorphism −174G/C and Serum Lipoprotein(a) Concentrations in Humans
por: Berthold, Heiner K., et al.
Publicado: (2011)

Inclisiran, Low-Density Lipoprotein Cholesterol and Lipoprotein (a)
por: Katsiki, Niki, et al.
Publicado: (2023)

Sex Disparities in the Treatment and Control of Cardiovascular Risk Factors in Type 2 Diabetes
por: Gouni-Berthold, Ioanna, et al.
Publicado: (2008)

Patterns and predictors of statin prescription in patients with type 2 diabetes
por: Berthold, Heiner K, et al.
Publicado: (2009)

PCSK9 Antibodies for the Treatment of Hypercholesterolemia
por: Gouni-Berthold, Ioanna, et al.
Publicado: (2014)

PCSK9 Monoclonal Antibodies: New Developments and Their Relevance in a Nucleic Acid–Based Therapy Era
por: Gouni-Berthold, Ioanna, et al.
Publicado: (2022)

Updates in Drug Treatment of Severe Hypertriglyceridemia
por: Gouni-Berthold, Ioanna, et al.
Publicado: (2023)

Molecular Lipids Identify Cardiovascular Risk and Are Efficiently Lowered by Simvastatin and PCSK9 Deficiency
por: Tarasov, Kirill, et al.
Publicado: (2014)

Low-density lipoprotein cholesterol goal attainment in Germany: Results from the DA VINCI study
por: Gouni-Berthold, Ioanna, et al.
Publicado: (2022)

The relationship between high density lipoprotein subclass profile and plasma lipids concentrations
por: Tian, Li, et al.
Publicado: (2010)

Evidence from a Randomized Trial That Simvastatin, but Not Ezetimibe, Upregulates Circulating PCSK9 Levels
por: Berthold, Heiner K., et al.
Publicado: (2013)

Association of the low-density lipoprotein cholesterol/high-density lipoprotein cholesterol ratio and concentrations of plasma lipids with high-density lipoprotein subclass distribution in the Chinese population
por: Tian, Li, et al.
Publicado: (2010)

Significant Quality of Life Improvement Observed in a Patient With FCS Associated With a Marked Reduction in Triglycerides
por: Gouni-Berthold, Ioanna
Publicado: (2019)

The Association between the Triglyceride to High-density Lipoprotein Cholesterol Ratio and Low-density Lipoprotein Subclasses
por: Moriyama, Kengo
Publicado: (2020)

Lipid-lowering therapies and achievement of LDL-cholesterol targets
por: Rizzo, Manfredi, et al.
Publicado: (2012)

Relationship between subclasses low-density lipoprotein and carotid plaque
por: Pan, Zhanhai, et al.
Publicado: (2022)

Randomized, Placebo-Controlled Trial of Mipomersen in Patients with Severe Hypercholesterolemia Receiving Maximally Tolerated Lipid-Lowering Therapy
por: McGowan, Mary P., et al.
Publicado: (2012)

The impact of plasma triglyceride and apolipoproteins concentrations on high-density lipoprotein subclasses distribution
por: Tian, Li, et al.
Publicado: (2011)

Are post-treatment low-density lipoprotein subclass pattern analyses potentially misleading?
por: Bays, Harold, et al.
Publicado: (2010)

The Value and Distribution of High-Density Lipoprotein Subclass in Patients with Acute Coronary Syndrome
por: Tian, Li, et al.
Publicado: (2014)

Main differences between two highly effective lipid-lowering therapies in subclasses of lipoproteins in patients with acute myocardial infarction
por: Pinto, Leticia C. S., et al.
Publicado: (2021)

Characteristics of High-density Lipoprotein Subclasses Distribution for Subjects with Desirable Total Cholesterol Levels
por: Tian, Li, et al.
Publicado: (2011)

Association between ethnicity and obesity with high-density lipoprotein (HDL) function and subclass distribution
por: Woudberg, Nicholas J., et al.
Publicado: (2016)

Association of High-Density Lipoprotein Subclasses with Chronic Kidney Disease Progression, Atherosclerosis, and Klotho
por: Kanda, Eiichiro, et al.
Publicado: (2016)

Anorexia Nervosa Is Associated with a Shift to Pro-Atherogenic Low-Density Lipoprotein Subclasses
por: Stadler, Julia T., et al.
Publicado: (2022)

A 3 year post‐intervention follow‐up on mortality in advanced heart failure (EVITA vitamin D supplementation trial)
por: Zittermann, Armin, et al.
Publicado: (2020)

PCSK9 Inhibition: Insights From Clinical Trials and Future Prospects
por: Katzmann, Julius L., et al.
Publicado: (2020)

Serum fatty acid and lipoprotein subclass concentrations and their associations in prepubertal healthy Norwegian children
por: Rajalahti, Tarja, et al.
Publicado: (2016)

High-density lipoprotein subclass and particle size in coronary heart disease patients with or without diabetes
por: Tian, Li, et al.
Publicado: (2012)

Physical Activity versus Sedentary Behavior: Associations with Lipoprotein Particle Subclass Concentrations in Healthy Adults
por: Aadland, Eivind, et al.
Publicado: (2013)

Physical activity, high density lipoprotein cholesterol and other lipids levels, in men and women from the ATTICA study
por: Skoumas, John, et al.
Publicado: (2003)

Association of High-Density Lipoprotein Subclasses with Carotid Intima-Media Thickness: Shimane CoHRE Study
por: Notsu, Yoshitomo, et al.
Publicado: (2018)

Plasma High Density Lipoprotein Small Subclass is Reduced in Alzheimer’s Disease Patients and Correlates with Cognitive Performance
por: Pedrini, Steve, et al.
Publicado: (2020)

Lipoprotein Subfractions in Metabolic Syndrome and Obesity: Clinical Significance and Therapeutic Approaches
por: Nikolic, Dragana, et al.
Publicado: (2013)

Low-grade inflammation is associated with a heterogeneous lipoprotein subclass profile in an apparently healthy population sample
por: Pontzen, Daniel L., et al.
Publicado: (2023)

Anti‐PCSK9 antibodies for hypercholesterolaemia: Overview of clinical data and implications for primary care
por: Descamps, Olivier S., et al.
Publicado: (2017)

Lower plasma cholesterol, LDL-cholesterol and LDL-lipoprotein subclasses in adult phenylketonuria (PKU) patients compared to healthy controls: results of NMR metabolomics investigation
por: Cannet, Claire, et al.
Publicado: (2020)

Particle Numbers of Lipoprotein Subclasses and Arterial Stiffness among Middle-aged men from the ERA JUMP study
por: Vishnu, Abhishek, et al.
Publicado: (2013)

Intensive lipid-lowering therapy, time to think beyond low-density lipoprotein cholesterol
por: Abdalwahab, Ahmed, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_fo717ouf7h7v6opkcp5o32rofu